4-(1,2,2-Trimethyl-propyl)-morpholine | 96921-32-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4-(1,2,2-Trimethyl-propyl)-morpholine
• 英文别名: 4-(3,3-Dimethylbutan-2-yl)morpholine
• CAS: 96921-32-3
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: OJLYQOQCXZUXLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(1-t-butylethenyl)morpholine 在 C₃₅H₃₂BF₁₀P 、 氢气 作用下， 以 氘代苯 为溶剂， 80.0 ℃ 、6.0 MPa 条件下， 反应 20.0h， 以37%的产率得到4-(1,2,2-Trimethyl-propyl)-morpholine
  参考文献：
  名称：

  为什么分子内三亚甲基桥连的受阻路易斯对Mes2PCH2CH2CH2B（C6F5）2不激活二氢？

  摘要：

  标为C的甲基3 -bridged沮丧膦硼烷的路易斯对（P / B FLP）2 B的制备是通过治疗的MES 2的PCl与甲代烯丙基格氏试剂，接着是抗马氏硼氢化与桥墩的硼烷[HB（C 6 ˚F 5）2）]。与C 2和C 4桥联的FLP类似物相比，FLP 2 b在典型的环境条件下对二氢没有活性。动态NMR光谱表明，这不是由于动力学阻碍了2 b的P⋅·⋅B解离。DFT计算表明母体化合物2 a的氢分解反应是显性的。的PH + / BH - ħ 2 -splitting的产物2b中被间接H的序列合成+ / H -加成。它在环境条件下损失了H 2，并证实了DFT分析的结果。

  DOI：

  10.1002/chem.201505200

文献信息

• New compounds
  申请人：Angbrant Joean

  公开号：US20080032968A1

  公开（公告）日：2008-02-07

  The present invention relates to novel compounds of formula (I): wherein m, n, R 0 , R 1 , R 2 , R 3 and R 4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT 6 receptor-related disorders.

  本发明涉及公式（I）的新化合物：其中m，n，R0，R1，R2，R3和R4如本文所述，以及包含这些化合物的制药组合物，用于它们的制备过程，以及用于制备针对5-HT6受体相关疾病的药物的化合物的用途。
• CHIRAL CONTROL
  申请人：WAVE LIFE SCIENCES PTE. LTD.

  公开号：US20150211006A1

  公开（公告）日：2015-07-30

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性控制的寡核苷酸、手性控制的寡核苷酸组合物以及其制备和使用方法。本发明特别涵盖了鉴定以前制备手性寡核苷酸方法中某些问题的来源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物。在某些实施例中，本发明提供了手性控制的寡核苷酸组合物。在某些实施例中，本发明提供了制备手性控制的寡核苷酸和手性控制的寡核苷酸组合物的方法。
• Chiral control
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10590413B2

  公开（公告）日：2020-03-17

  The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

  本发明涉及手性受控寡核苷酸、手性受控寡核苷酸组合物以及制作和使用方法。本发明具体包括确定先前制备手性寡核苷酸方法中某些问题的根源，包括禁止制备完全手性控制的组合物，特别是包含多种寡核苷酸类型的组合物的问题。在某些实施方案中，本发明提供了手性控制的寡核苷酸组合物。在一些实施方案中，本发明提供了制作手性控制寡核苷酸和手性控制寡核苷酸组合物的方法。
• Oligonucleotide compositions and methods thereof
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10724035B2

  公开（公告）日：2020-07-28

  Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.

  除其他外，本公开涉及选择设计的手性控制寡核苷酸、手性控制寡核苷酸组合物以及制造和使用方法。在一些实施方案中，所提供的手性控制寡核苷酸组合物提供了与参考寡核苷酸组合物不同的核酸聚合物裂解模式。在一些实施方案中，所提供的手性控制寡核苷酸组合物在核酸聚合物的互补序列内提供单位点裂解。在一些实施方案中，手性控制寡核苷酸组合物具有本文所述的任何碱基序列和/或模式或碱基修饰、糖修饰、骨架修饰和/或立体化学，或这些元素的组合。
• Chiral design
  申请人：WAVE LIFE SCIENCES LTD.

  公开号：US10815482B2

  公开（公告）日：2020-10-27

  The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.

  本发明涉及精选设计的手性控制寡核苷酸、手性控制寡核苷酸组合物以及制造和使用它们的方法。在一些实施方案中，所提供的手性控制寡核苷酸组合物提供了与参考寡核苷酸组合物不同的核酸聚合物裂解模式。在一些实施方案中，所提供的手性控制寡核苷酸组合物在核酸聚合物的互补序列内提供单位点裂解。